Get the Stockscreener App
8.28
7.07%
-0.63
Personalis Inc stock is traded at $8.28, with a volume of 1.39M.
It is down -7.07% in the last 24 hours and down -11.82% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$8.91
Open:
$8.61
24h Volume:
1.39M
Relative Volume:
1.00
Market Cap:
$735.30M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-3.68
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
+0.85%
1M Performance:
-11.82%
6M Performance:
+78.45%
1Y Performance:
+52.49%
1-Day Range:
$8.01
$8.84
1-Week Range:
$8.01
$9.558
52-Week Range:
$2.8262
$11.50
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
8.28 | 791.25M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
510.93 | 193.53B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
209.50 | 149.33B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
635.66 | 50.36B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
122.90 | 35.73B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
333.33 | 32.24B | 3.17B | 642.63M | 539.81M | 10.77 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
How Personalis Inc. stock performs in weak economyJuly 2025 Macro Moves & Entry Point Confirmation Alerts - mfd.ru
Personalis (NASDAQ:PSNL) Shares Down 4.8%Should You Sell? - MarketBeat
Aberdeen Group plc Increases Stock Position in Personalis, Inc. $PSNL - MarketBeat
Personalis (PSNL) to Release Earnings on Thursday - MarketBeat
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference - BioSpace
Personalis (NASDAQ:PSNL) Trading Up 6.2%Time to Buy? - MarketBeat
Personalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-Therapy - MSN
Why Personalis Inc. stock could benefit from AI revolutionJuly 2025 Movers & Low Risk Growth Stock Ideas - mfd.ru
Personalis gains as VA awards work order worth up to $13.5M - MSN
Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug Mood: Is Personalis Inc showing insider buyingTrade Entry Report & Real-Time Price Movement Reports - baoquankhu1.vn
Personalis, Inc. (PSNL) Stock Analysis: Evaluating a 34.51% Upside Potential in the Diagnostics Sector - DirectorsTalk Interviews
Aug Patterns: Will Personalis Inc outperform small cap indexesJuly 2025 Volume & Capital Protection Trade Alerts - baoquankhu1.vn
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Why Personalis Stock Is Rising: Medicare Covers Luncg Cancer MRD Test - MSN
Personalis Data Breach Lawsuit Investigation - Claim Depot
Medicare Now Covers NeXT Personal® MRD Testing for Lung Cancer SurveillancePersonalis, Inc. - Oncodaily
Personalis (NASDAQ:PSNL) Price Target Raised to $13.00 - MarketBeat
Will Personalis Inc. outperform small cap indexesJuly 2025 Big Picture & High Conviction Investment Ideas - mfd.ru
Medicare approves Personalis’ lung cancer test for surveillance By Investing.com - Investing.com Australia
Biotech operator Personalis sees 10% spike from Medicare covering lung cancer blood test - Mugglehead Investment Magazine
Personalis (PSNL) Gains 10% Following Medicare Coverage for Canc - GuruFocus
Medicare approves Personalis’ lung cancer test for surveillance - Investing.com Nigeria
Personalis stock rises after Medicare approves lung cancer test coverage - Investing.com South Africa
Personalis (NASDAQ:PSNL) Shares Gap UpShould You Buy? - MarketBeat
Personalis stock rises after Medicare approves lung cancer test coverage By Investing.com - Investing.com Australia
Personalis wins Medicare coverage for NeXT Personal (PSNL) - Seeking Alpha
Why Is Personalis Stock Soaring Tuesday?Personalis (NASDAQ:PSNL) - Benzinga
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Asianet Newsable
Personalis rises as Medicare extends coverage to lung cancer test - TradingView
Personalis Inc receives Medicare coverage for Next Personal in lung cancer surveillance - marketscreener.com
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance - Business Wire
Personalis Inc Receives Medicare Coverage For Next Personal In Lung Cancer Surveillance - TradingView
Revenue Check: Can Personalis Inc stock double in the next yearJuly 2025 Reactions & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Wellington Shields Capital Management LLC Cuts Stake in Personalis, Inc. $PSNL - MarketBeat
Breakthrough Cancer Monitoring Technique Fuels Growth for Personalis - AD HOC NEWS
Aug Final Week: Is Personalis Inc showing insider buyingLong Setup & AI Enhanced Trading Signals - baoquankhu1.vn
Personalis, Inc. (PSNL): A Bull Case Theory - Yahoo Finance
Personalis (PSNL) Study Highlights NeXT Personal's Impact in Can - GuruFocus
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors - Business Wire
Personalis, Inc. (PSNL) Stock Analysis: A 11.76% Potential Upside Amidst Revenue Challenges - DirectorsTalk Interviews
Wall Street Zen Upgrades Personalis (NASDAQ:PSNL) to Hold - MarketBeat
Is Personalis Inc.’s growth already priced inJuly 2025 Recap & Consistent Return Strategy Ideas - mfd.ru
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - BioSpace
Insider Selling: Personalis (NASDAQ:PSNL) CFO Sells $13,811.50 in Stock - Defense World
What 9 Analyst Ratings Have To Say About Personalis - Benzinga
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Personalis Inc Stock (PSNL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tempus AI, Inc. | 10% Owner |
Nov 25 '25 |
Buy |
10.62 |
23,600 |
250,665 |
12,918,346 |
| Tempus AI, Inc. | 10% Owner |
Dec 22 '25 |
Buy |
8.93 |
28,000 |
250,040 |
13,039,067 |
| Tempus AI, Inc. | 10% Owner |
Nov 21 '25 |
Buy |
9.40 |
26,499 |
249,190 |
12,869,521 |
| Tempus AI, Inc. | 10% Owner |
Nov 24 '25 |
Buy |
9.87 |
25,225 |
248,971 |
12,894,746 |
| Tempus AI, Inc. | 10% Owner |
Nov 19 '25 |
Buy |
8.12 |
30,645 |
248,837 |
12,814,195 |
| Tempus AI, Inc. | 10% Owner |
Nov 20 '25 |
Buy |
8.63 |
28,827 |
248,777 |
12,843,022 |
| Tempus AI, Inc. | 10% Owner |
Dec 17 '25 |
Buy |
7.86 |
31,650 |
248,769 |
12,949,996 |
| Tempus AI, Inc. | 10% Owner |
Dec 19 '25 |
Buy |
8.39 |
29,641 |
248,688 |
13,011,067 |
| Tempus AI, Inc. | 10% Owner |
Dec 18 '25 |
Buy |
7.91 |
31,430 |
248,611 |
12,981,426 |
| Tachibana Aaron | CFO AND COO |
Jan 22 '26 |
Option Exercise |
9.16 |
1,201 |
11,001 |
165,659 |
0.01%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):